Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue Estimates

Group 1 - Bristol Myers Squibb reported quarterly earnings of $1.67 per share, exceeding the Zacks Consensus Estimate of $1.46 per share, but down from $1.70 per share a year ago, representing an earnings surprise of 14.38% [1] - The company achieved revenues of $12.34 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 6.59% and up from $11.48 billion year-over-year [2] - Bristol Myers has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 5.6% since the beginning of the year, outperforming the S&P 500's gain of 3.1% [3] - The future performance of Bristol Myers' stock will largely depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - Current consensus EPS estimate for the upcoming quarter is $1.66 on revenues of $11.32 billion, and for the current fiscal year, it is $6.98 on revenues of $46.32 billion [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Bristol Myers is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]